Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives Consensus Rating of “Moderate Buy” from Analysts

Tyra Biosciences, Inc. (NASDAQ:TYRA) has been given a consensus rating of “Moderate Buy” by the fourteen research firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and twelve have given a buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $48.2222.

TYRA has been the topic of several research analyst reports. JonesTrading began coverage on Tyra Biosciences in a report on Wednesday, June 17th. They issued a “buy” rating and a $56.00 price objective on the stock. HC Wainwright restated a “buy” rating and issued a $45.00 price target on shares of Tyra Biosciences in a research note on Friday. Bank of America upped their target price on shares of Tyra Biosciences from $37.00 to $42.00 and gave the stock a “buy” rating in a research note on Wednesday, June 10th. Wolfe Research initiated coverage on Tyra Biosciences in a research report on Tuesday, May 19th. They set a “peer perform” rating for the company. Finally, Jefferies Financial Group restated a “buy” rating and set a $42.00 target price on shares of Tyra Biosciences in a research note on Wednesday, August 5th.

Tyra Biosciences Stock Performance

TYRA opened at $28.65 on Monday. Tyra Biosciences has a one year low of $11.70 and a one year high of $40.65. The business’s 50 day moving average price is $29.02 and its 200 day moving average price is $32.05. The stock has a market capitalization of $1.71 billion, a PE ratio of -11.94 and a beta of 0.73.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). As a group, equities research analysts forecast that Tyra Biosciences will post -2.74 earnings per share for the current fiscal year.

Institutional Trading of Tyra Biosciences

A number of large investors have recently bought and sold shares of the business. AQR Capital Management LLC increased its stake in shares of Tyra Biosciences by 2.0% during the fourth quarter. AQR Capital Management LLC now owns 28,631 shares of the company’s stock worth $753,000 after acquiring an additional 562 shares during the period. MetLife Investment Management LLC increased its holdings in Tyra Biosciences by 5.0% in the fourth quarter. MetLife Investment Management LLC now owns 15,356 shares of the company’s stock valued at $404,000 after buying an additional 725 shares in the last quarter. Virtus Investment Advisers LLC lifted its position in shares of Tyra Biosciences by 6.7% during the 4th quarter. Virtus Investment Advisers LLC now owns 11,756 shares of the company’s stock valued at $309,000 after acquiring an additional 741 shares during the period. Hilton Head Capital Partners LLC acquired a new position in Tyra Biosciences during the first quarter worth $30,000. Finally, Deutsche Bank AG boosted its position in shares of Tyra Biosciences by 5.8% in the 4th quarter. Deutsche Bank AG now owns 16,377 shares of the company’s stock worth $431,000 after buying an additional 894 shares in the last quarter. Institutional investors and hedge funds own 84.14% of the company’s stock.

About Tyra Biosciences

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.